Last reviewed · How we verify
Adrenocorticotropic Hormone Gel
At a glance
| Generic name | Adrenocorticotropic Hormone Gel |
|---|---|
| Also known as | H.P. Acthar Gel, Repository Corticotropin Injection, Acthar gel, ACTH |
| Sponsor | Rohit Aggarwal, MD |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Headache
- Urinary tract infection
- Upper respiratory tract infection
- Hypertension
- Insomnia
- Nasopharyngitis
- Weight Gain
- Oedema
- Hypokalaemia
- Fatigue
- Diarrhoea
- Oedema peripheral
Key clinical trials
- ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study) (PHASE2)
- Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease (PHASE4)
- ACTHar in the Treatment of Lupus Nephritis (PHASE4)
- ACTH in Progressive Forms of MS (PHASE2)
- Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis (PHASE4)
- A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy (PHASE3)
- The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis (PHASE3)
- Ocular Sarcoidosis Open Label Trial of ACTHAR Gel (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adrenocorticotropic Hormone Gel CI brief — competitive landscape report
- Adrenocorticotropic Hormone Gel updates RSS · CI watch RSS
- Rohit Aggarwal, MD portfolio CI